[HTML][HTML] Interrater agreement and reliability of PERCIST and visual assessment when using 18F-FDG-PET/CT for response monitoring of metastatic breast cancer
JS Sørensen, MH Vilstrup, J Holm, M Vogsen, JL Bülow… - Diagnostics, 2020 - mdpi.com
Response evaluation at regular intervals is indicated for treatment of metastatic breast
cancer (MBC). FDG-PET/CT has the potential to monitor treatment response accurately. Our …
cancer (MBC). FDG-PET/CT has the potential to monitor treatment response accurately. Our …
Interrater Agreement and Reliability of PERCIST and Visual Assessment When Using 18F-FDG-PET/CT for Response Monitoring of Metastatic Breast Cancer
JS Sørensen, MH Vilstrup, J Holm… - Diagnostics (Basel …, 2020 - pubmed.ncbi.nlm.nih.gov
Response evaluation at regular intervals is indicated for treatment of metastatic breast
cancer (MBC). FDG-PET/CT has the potential to monitor treatment response accurately. Our …
cancer (MBC). FDG-PET/CT has the potential to monitor treatment response accurately. Our …
[HTML][HTML] Interrater Agreement and Reliability of PERCIST and Visual Assessment When Using 18F-FDG-PET/CT for Response Monitoring of Metastatic Breast Cancer
JS Sørensen, MH Vilstrup, J Holm, M Vogsen… - Diagnostics, 2020 - ncbi.nlm.nih.gov
Response evaluation at regular intervals is indicated for treatment of metastatic breast
cancer (MBC). FDG-PET/CT has the potential to monitor treatment response accurately. Our …
cancer (MBC). FDG-PET/CT has the potential to monitor treatment response accurately. Our …
[PDF][PDF] Interrater Agreement and Reliability of PERCIST and Visual Assessment When Using 18F-FDG-PET/CT for Response Monitoring of Metastatic Breast Cancer
JS Sørensen, MH Vilstrup, J Holm, M Vogsen, JL Bülow… - pdfs.semanticscholar.org
Response evaluation at regular intervals is indicated for treatment of metastatic breast
cancer (MBC). FDG-PET/CT has the potential to monitor treatment response accurately. Our …
cancer (MBC). FDG-PET/CT has the potential to monitor treatment response accurately. Our …
Interrater Agreement and Reliability of PERCIST and Visual Assessment When Using 18F-FDG-PET/CT for Response Monitoring of Metastatic Breast Cancer.
JS Sørensen, MH Vilstrup, J Holm… - Diagnostics (2075 …, 2020 - search.ebscohost.com
Response evaluation at regular intervals is indicated for treatment of metastatic breast
cancer (MBC). FDG-PET/CT has the potential to monitor treatment response accurately. Our …
cancer (MBC). FDG-PET/CT has the potential to monitor treatment response accurately. Our …
Interrater Agreement and Reliability of PERCIST and Visual Assessment When Using 18F-FDG-PET/CT for Response Monitoring of Metastatic Breast Cancer
JS Sørensen, MH Vilstrup, J Holm… - …, 2020 - portal.findresearcher.sdu.dk
Response evaluation at regular intervals is indicated for treatment of metastatic breast
cancer (MBC). FDG-PET/CT has the potential to monitor treatment response accurately. Our …
cancer (MBC). FDG-PET/CT has the potential to monitor treatment response accurately. Our …
Interrater Agreement and Reliability of PERCIST and Visual Assessment When Using 18F-FDG-PET/CT for Response Monitoring of Metastatic Breast Cancer
JS Sørensen, MH Vilstrup, J Holm, M Vogsen, JL Bülow… - search.proquest.com
Response evaluation at regular intervals is indicated for treatment of metastatic breast
cancer (MBC). FDG-PET/CT has the potential to monitor treatment response accurately. Our …
cancer (MBC). FDG-PET/CT has the potential to monitor treatment response accurately. Our …
Interrater Agreement and Reliability of PERCIST and Visual Assessment When Using 18F-FDG-PET/CT for Response Monitoring of Metastatic Breast Cancer.
JS Sørensen, MH Vilstrup, J Holm… - Diagnostics (Basel …, 2020 - europepmc.org
Response evaluation at regular intervals is indicated for treatment of metastatic breast
cancer (MBC). FDG-PET/CT has the potential to monitor treatment response accurately. Our …
cancer (MBC). FDG-PET/CT has the potential to monitor treatment response accurately. Our …